Laboratory Testing for Mast Cell Activation Syndrome

Essential Mast Cell Mediator Testing

• The American Academy of Allergy, Asthma, and Immunology recommends obtaining baseline serum tryptase when the patient is asymptomatic to establish their personal reference value 1, 2
• The American Academy of Allergy, Asthma, and Immunology suggests collecting acute serum tryptase 1-4 hours after symptom onset during a suspected mast cell activation episode 1, 2
• An increase of ≥20% above baseline PLUS an absolute increase of ≥2 ng/mL in serum tryptase confirms mast cell activation, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
• Comparing acute to baseline levels is optimal for tryptase as a preformed mediator, as stated by the American Academy of Allergy, Asthma, and Immunology 1, 3
• N-methylhistamine, a histamine metabolite, is a more reliable marker than direct histamine measurement, which is not recommended by the American Academy of Allergy, Asthma, and Immunology 1, 3
• Leukotriene E4 peaks in 0-6 hour collections after episodes and can guide leukotriene antagonist therapy, according to the American Academy of Allergy, Asthma, and Immunology 1
• 11β-prostaglandin F2α peaks in 0-3 hour collections and correlates with anaphylactic severity, as stated by the American Academy of Allergy, Asthma, and Immunology 1

Genetic and Clonality Testing

• The National Comprehensive Cancer Network recommends using highly sensitive allele-specific oligonucleotide quantitative PCR (ASO-qPCR) to identify clonal MCAS through KIT D816V mutation testing 4, 2, 5
• The American Academy of Allergy, Asthma, and Immunology suggests using buccal swab for TPSAB1 α-tryptase copy number variation (CNV) to diagnose hereditary α-tryptasemia 2, 5, 3

Bone Marrow Evaluation

• The National Comprehensive Cancer Network recommends bone marrow biopsy for patients with baseline serum tryptase persistently >20 ng/mL 4
• Bone marrow analysis components include aspirate, core biopsy, immunohistochemistry, and flow cytometry to evaluate mast cell burden and identify aberrant expression, as stated by the National Comprehensive Cancer Network 4
• KIT D816V mutation testing on bone marrow is recommended if peripheral blood is negative, using highly sensitive assays, according to the National Comprehensive Cancer Network 4

Tests NOT Recommended

• The American Academy of Allergy, Asthma, and Immunology does not recommend plasma or urine histamine levels, instead suggesting the use of N-methylhistamine 1, 3
• Heparin is not validated as a marker of mast cell activation, according to the American Academy of Allergy, Asthma, and Immunology 1, 3
• Chromogranin A is not a reliable marker for mast cell activation, as it resides in neuroendocrine cells, not mast cells, as stated by the American Academy of Allergy, Asthma, and Immunology 1, 3

Practical Testing Algorithm

• The American Academy of Allergy, Asthma, and Immunology recommends an initial workup during symptomatic episodes, including serum tryptase and 24-hour urine collection for N-methylhistamine, LTE4, and 11β-PGF2α 1, 2
• Clonality assessment includes peripheral blood KIT D816V mutation testing and buccal swab for TPSAB1 α-tryptase CNV, as recommended by the American Academy of Allergy, Asthma, and Immunology 4, 2, 5
• Bone marrow evaluation is only recommended if baseline tryptase >20 ng/mL persistently, or if there are clinical features suggesting systemic mastocytosis, according to the National Comprehensive Cancer Network 4

Diagnostic Testing and Treatment of Mast Cell Activation Syndrome

Introduction to Diagnostic Criteria

• The diagnosis of Mast Cell Activation Syndrome (MCAS) requires meeting three specific criteria simultaneously: clinical symptoms, laboratory evidence, and treatment response, as recommended by the Journal of Allergy and Clinical Immunology 6, 7
• Clinical symptoms include episodic signs of systemic mast cell activation affecting at least 2 organ systems, such as skin, gastrointestinal, cardiovascular, respiratory, or neurologic, according to the Journal of Allergy and Clinical Immunology 6, 8
• Laboratory evidence involves documented increase in mast cell mediators during symptomatic episodes, as stated by the Journal of Allergy and Clinical Immunology 6, 7
• Treatment response is defined as improvement with medications blocking mast cell mediators or their production, as noted by the Journal of Allergy and Clinical Immunology 6, 7

Diagnostic Testing

• Obtain serum tryptase at baseline and 1-4 hours after symptom onset, looking for an increase of ≥20% above baseline plus 2 ng/mL, as recommended by the Journal of Allergy and Clinical Immunology 6, 7
• Consider 24-hour urine collection for N-methylhistamine, leukotriene E4, and 11β-prostaglandin F2α when serum tryptase is difficult to obtain or negative, according to the Journal of Allergy and Clinical Immunology 6, 7
• Bone marrow biopsy is indicated if baseline serum tryptase is persistently >20 ng/mL, or if there are adult-onset mastocytosis in the skin, abnormal blood counts, or organomegaly, as stated by the Journal of the National Comprehensive Cancer Network 9, 10

Treatment

• Initiate treatment with nonsedating H1 antihistamines at 2-4 times standard doses, combined with H2 antihistamines, and add oral cromolyn sodium for gastrointestinal symptoms, as recommended by the Journal of Allergy and Clinical Immunology 6, 7, 11
• Use leukotriene antagonists, such as montelukast or zileuton, if urinary LTE4 is elevated, as noted by the Journal of Allergy and Clinical Immunology 6, 7, 12
• Consider aspirin therapy if prostaglandin metabolites are elevated, but use with caution due to the risk of triggering mast cell activation, as stated by the Journal of Allergy and Clinical Immunology 6, 7, 12

Management of Acute Episodes

• For anaphylaxis, assume a supine position, administer intramuscular epinephrine, and call emergency services, as recommended by the Journal of Allergy and Clinical Immunology 11
• Use supplemental oxygen, IV fluids, and secondary management with chlorphenamine and hydrocortisone, as noted by Praxis Medical Insights 13

Trigger Avoidance and Special Considerations

• Identify and eliminate specific triggers, such as insect venoms, temperature extremes, mechanical irritation, alcohol, and certain medications, as recommended by the Journal of Allergy and Clinical Immunology 11, 12, 13
• Use caution with opioids, as they may trigger mast cell activation, but do not categorically avoid their use, as stated by Praxis Medical Insights 12
• Coordinate perioperative management with anesthesia and surgical teams, and consider pre-anesthetic treatment with anxiolytics, antihistamines, and corticosteroids, as recommended by the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 9, 10, 13

Diagnostic Criteria for Mast Cell Activation Syndrome (MCAS)

Laboratory Criteria: Documented Mast Cell Mediator Elevation

• The American Gastroenterological Association recommends obtaining baseline serum tryptase when the patient is completely asymptomatic to establish their personal reference value, and during a suspected mast cell activation episode, collect acute serum tryptase 1-4 hours after symptom onset 14
• The diagnostic threshold for serum tryptase is an increase ≥20% above the patient's baseline PLUS an absolute increase ≥2 ng/mL, as recommended by the American Gastroenterological Association 14, 15, 16

Additional Diagnostic Testing to Classify MCAS Subtype

• The National Comprehensive Cancer Network recommends peripheral blood KIT D816V mutation testing using highly sensitive allele-specific oligonucleotide quantitative PCR (ASO-qPCR) to identify clonal (primary) MCAS 17, 18
• Bone marrow biopsy is indicated if baseline serum tryptase persistently >20 ng/mL or clinical features suggesting systemic mastocytosis, and should include aspirate and core biopsy, flow cytometry, immunohistochemistry, cytogenetics, and FISH for associated hematologic neoplasm-related abnormalities, as recommended by the National Comprehensive Cancer Network 17, 18

Practical Diagnostic Algorithm

• The National Comprehensive Cancer Network recommends excluding secondary causes, such as IgE-mediated allergies, drug reactions, and infections, to confirm the diagnosis of MCAS 17, 18
• The American Gastroenterological Association recommends confirming treatment response by documenting improvement with mast cell-targeted therapies, and referring patients to an allergy specialist or mast cell disease research center for additional testing and management 14, 15, 16

Guidelines for Differentiating Mast Cell Activation Syndrome (MCAS) from Histamine Intolerance

Diagnostic Criteria

• Core definition of MCAS: Requires (1) recurrent episodic symptoms affecting ≥ two organ systems simultaneously, (2) documented elevation of mast‑cell mediators in ≥ two separate symptomatic episodes, and (3) clinical improvement with mast‑cell‑targeted therapy. 19
• Histamine intolerance profile: Characterized by chronic gastrointestinal complaints that involve only a single organ system and lack episodic mediator spikes. 20

Clinical Pattern Recognition

• Multisystem involvement in MCAS: Typical simultaneous manifestations include cardiovascular signs (hypotension, tachycardia, syncope), dermatologic signs (urticaria, flushing, angio‑edema), respiratory signs (wheezing, dyspnea, inspiratory stridor), and gastrointestinal signs (crampy abdominal pain, diarrhea, nausea, vomiting). 19
• Single‑organ presentation excludes MCAS: Isolated gastrointestinal symptoms without concurrent involvement of other systems do not satisfy MCAS criteria. 20

Laboratory Evaluation

The acute tryptase rise must be documented in ≥ two separate episodes to confirm MCAS. 19

Therapeutic Response as Diagnostic Confirmation

• Required MCAS response: Symptom improvement with a regimen that includes high‑dose H1 antihistamines (2–4 × standard dose) plus H2 antihistamines, mast‑cell stabilizer (cromolyn 200 mg four times daily), and, when urinary LTE4 is elevated, a leukotriene receptor antagonist (e.g., montelukast). 19
• Histamine intolerance management: Primarily dietary (low‑histamine diet) and, optionally, diamine oxidase supplementation; antihistamines may help but are not diagnostic. 20

Differential Diagnosis & Exclusion Criteria

• Before confirming MCAS, rule out:
  
  • IgE‑mediated allergic diseases 19
  • Drug‑induced reactions 19
  • Autonomic dysfunction such as POTS 20
  • Functional gastrointestinal disorders (e.g., irritable bowel syndrome) 20
  • Hereditary alpha‑tryptasemia (TPSAB1 duplication) 19

Advanced Diagnostic Testing (when MCAS criteria are met)

• KIT D816V mutation analysis in peripheral blood by high‑sensitivity ASO‑qPCR to identify clonal MCAS. 19
• TPSAB1 α‑tryptase copy‑number assessment (buccal swab) to exclude hereditary alpha‑tryptasemia. 19
• Bone‑marrow biopsy only if baseline tryptase remains > 20 ng/mL or systemic mastocytosis is suspected. 19
• Referral to an allergy specialist or dedicated mast‑cell center for comprehensive evaluation. 19, 20

Decision‑Aid Summary

• Likely MCAS if the patient experiences acute, recurrent attacks with symptom‑free intervals, simultaneous involvement of ≥ two organ systems, documented tryptase rises meeting the ≥ 20 % + ≥ 2 ng/mL threshold in ≥ two episodes, and demonstrable improvement with mast‑cell‑directed therapy. 19
• Likely Histamine Intolerance if the patient has chronic, persistent gastrointestinal symptoms confined to a single organ system, normal baseline tryptase without episodic spikes, and symptom relief with a low‑histamine diet. 20

Evidence level for all statements: not explicitly graded in source documents.

Diagnostic Criteria and Structured Approach for Mast Cell Activation Syndrome

Diagnostic Criteria

• MCAS diagnosis requires all three mandatory criteria: (1) recurrent episodic symptoms affecting ≥ two organ systems simultaneously, (2) documented elevation of mast‑cell mediators on ≥ two separate symptomatic episodes, and (3) demonstrable clinical improvement with mast‑cell‑targeted therapy. 21

Clinical Recognition – Multi‑System Involvement

• Episodes must involve at least two of the following organ systems: cardiovascular (e.g., hypotension, tachycardia), dermatologic (e.g., urticaria, flushing), gastrointestinal (e.g., abdominal pain, diarrhea), respiratory (e.g., wheezing, dyspnea), and neurologic (e.g., headache, brain fog). 21

Laboratory Confirmation

Serum Tryptase

• Obtain a baseline serum tryptase when the patient is asymptomatic to establish an individual reference value. 21
• During an acute episode, collect serum tryptase 1–4 hours after symptom onset (optimal 30–120 min). The diagnostic threshold is ≥ 20 % increase above baseline + absolute increase ≥ 2 ng/mL, and this elevation must be documented on ≥ two separate occasions. 21

Urine Mediator Testing (when tryptase unavailable or negative)

• Perform a 24‑hour urine collection for the following metabolites:
  
  • N‑methylhistamine – preferred over direct plasma/serum histamine. 21
  • Leukotriene E4 (LTE4) – peaks 0–6 h after episodes and guides leukotriene‑antagonist therapy. 21
  • 11β‑prostaglandin F₂α – peaks 0–3 h, correlates with anaphylactic severity and suggests potential aspirin benefit. 21

Mandatory Therapeutic Response Criterion

• Demonstrated clinical improvement with mast‑cell‑targeted therapy is required:
  
  • H1 antihistamines at 2–4 × the standard FDA‑approved dose (e.g., cetirizine 20–40 mg daily).
  • H2 antihistamines (e.g., famotidine 20–40 mg twice daily). 21
  • Mast‑cell stabilizers (e.g., cromolyn sodium 200 mg four times daily).
  • Leukotriene antagonists (e.g., montelukast 10 mg daily) when urinary LTE4 is elevated.
• Therapeutic response should be evaluated over 2–6 weeks before escalating treatment or declaring failure. 21

Exclusion of Secondary Causes

• Systematically rule out identifiable triggers before labeling a case as primary/idiopathic MCAS, including IgE‑mediated allergies, drug reactions, infections, autonomic dysfunction, functional gastrointestinal disorders, and physical triggers such as exercise, temperature extremes, or pressure. Physical triggers are specifically highlighted. 21

Subtype Classification

Primary (Clonal) MCAS

• Peripheral blood KIT D816V mutation testing (high‑sensitivity ASO‑qPCR) identifies clonal mast‑cell disease and is present in systemic mastocytosis and clonal MCAS. 21
• Buccal‑swab TPSAB1 α‑tryptase copy‑number variation testing diagnoses hereditary alpha‑tryptasemia, a genetic condition with chronically elevated baseline tryptase (often > 8–10 ng/mL). 21
• Bone‑marrow biopsy is indicated when:
  
  • Baseline tryptase persistently > 20 ng/mL,
  • Clinical features suggest systemic mastocytosis (e.g., adult‑onset urticaria pigmentosa, organomegaly, cytopenias), or
  • KIT testing is negative but suspicion remains high. 21

Secondary MCAS

• Normal mast cells activated by identifiable external triggers; no KIT mutations or aberrant CD25 expression are found. 21

Idiopathic MCAS

• Diagnosis of exclusion when no trigger, mutation, or genetic trait is identified after comprehensive evaluation. 21

Practical Diagnostic Algorithm (Summary)

Common Diagnostic Pitfalls (Cited)

• Overdiagnosis occurs when:

  • Only a single organ system is involved,
  • Symptoms are chronic and persistent without episodic attacks,
  • Mediator elevation is not documented, or
  • There is no therapeutic response to appropriately dosed mast‑cell‑targeted agents. 21

• Hereditary alpha‑tryptasemia can mimic MCAS but is a distinct genetic disorder; TPSAB1 testing is required for differentiation. 21

• Inadequate antihistamine dosing (using standard rather than 2–4 × dose) may falsely suggest treatment resistance; ensure appropriate dosing and duration before escalation. 21

Clinical Presentation and Diagnostic Features of Mast Cell Activation Syndrome

Dermatologic Manifestations

Gastrointestinal Manifestations

Cardiovascular Manifestations

Respiratory Manifestations

Severe Systemic Manifestations

Pediatric vs. Adult Presentation

Laboratory Evidence of Mast Cell Activation

Diagnostic Pitfalls

Common Triggers